Novo Nordisk(NVO)2025-02-05 12:04Financial Performance - Novo Nordisk's sales in Russia and Ukraine accounted for less than 1% of global sales in 2024, with over 700,000 patients in Russia receiving essential medication[82]. - The most significant source of cash flow from operating activities is sales of Diabetes and Obesity care and Rare disease products, influenced by pricing, volume, product mix, costs, and exchange rates[90]. - Novo Nordisk believes its financial resources are sufficient to meet requirements for at least the next 12 months[88]. - The company has obtained credit ratings from two independent external rating agencies, reflecting its financial stability[87]. Operational Challenges - The company has ceased filing for marketing authorizations of new medication in Russia and suspended further clinical investments in the region[82]. - Novo Nordisk's medicines are currently available in more than 90% of Ukraine, ensuring continued supply despite ongoing challenges[82]. - Future performance may be affected by various risks, including currency exchange rate fluctuations and interruptions in supply chains[9]. Financial Management - The company maintains a centralized approach to financial risk management, governed by the Novo Nordisk Treasury Policy[86]. - Cash flow statements and balance sheets for 2024 are detailed on pages 103 and 104 of the Annual Report 2024, respectively[87]. - Novo Nordisk's trade receivable program details are available in Note 4.4 of the consolidated financial statements[91].